risk....Yes, I think the lipids test is a ways away, as far as regulatory. But, like LympPro, it does not require CLIA for sales to RUO. AMBS Dx is in great shape. I think the company understands that they must go multivariate for LymPro to pass CLIA. And they are working on that. But for now, RUO customers could possibly use G'Town test as a quasi added marker to LymPro, making for tighter accuracy. I was not a fan of LymPro, or of diagnostics division. Nor was I a fan of issuing new shares for acquisitions. Add MS Precise too, and now I'm fired up about the whole program. The greatest risk in the stock is the company's financial status. That risk will go away with monetization of Diagnostics, which should happen in 2015. Also, it's very important that this happens before any therapeutics partnerships, so as to negotiate from a position of strength.
risk....."Too large for you"? Really? This is nothing more than more bureaucracy. As for Stern, this guy is biased against LymPro. He said less than a year ago, that a blood test for Alzheimer's is ten years from market. And, he sells his own cognitive test for Alzheimer's that sells for $500 a pop. I don't know why GC trusts this guy.
I've placed my bet on Amarantus. I thought I had all the shares that I wanted, but couldn't resist adding a few yesterday at this ridiculous price. I have little doubt that this company will one day be a powerhouse bio-tech. But today's press release, I don't like it one bit.
lyondell.....I just got back to the (home) office, and coincidentally, was also going to give my temporary farewell. I hope you don't mind my joining you. I'll see you all later. Stay long, my friends.
chees.....Give the guy (I'm assuming it's a guy) a break. To him, he is invested. Small money, but at least he isn't acting like a #$%$, like many on here.
Anyone who holds this stock until MANF is in its full glory, will probably become wealthy, assuming that day comes. And I think it will. As for price targets in and out, forget that, no comment.
nidan.....The beauty of this is that Dr. Wen is not biased towards Amarantus. Thus, a strong endorsement.
nidan.....I agree. Many, if not most AMBS investors are here because of the company's powerful assets. The company must increase its exposure. I think that there is too much paranoia resulting from last summer's penny pumping debacle. There is no need to feel guilty about promoting the company's pipe.
risk.....Yes it is. I read it with my own two eyes. For the life of me though, I can't remember where I read it, and am having no success in finding reference point.
At One Med Forum..... Bascom Palmer, the consensus #1 eye institute in the entire world, made the claim that there has never been a compound in history that has been proven to protect rods and cones better than MANF. The world needs to be exposed to this wonder molecule. Next week will be a start.
smitty.....100 to 1 R/S. Then raise authorized shares from 20 million to 40 million. Then again from 40 million to a hundred million. All done with a calculated spin that blind shareholders submit to. By the time all this happens, the company might have built itself up to a billion dollar market cap. But, with a split-adjusted ten billion shares.... Wow! Four or five years from now, the stock price has climbed to ten cents !!!
I hope this scenario is just a mythical doom and gloom. Hey, GC. STOP ISSUING NEW STOCK !!!!!
watson....."MANF will license in pieces..." This is what I'm hoping for. They must get to an end game when it comes to dilution... Find a suitor for R.P. !!! I have no doubts that AMBS' market cap will most likely at least double in 2015. But this will be of no benefit to shareholders if their only source of funding is to print more stock. I'm tired of it. More like exhausted. "We're waiting for a better deal." Do shareholders really want to hear more of that? I don't. Find a partner for Retinitis Pigmentosa. Stop watering down my cut of the company. There are plenty of other indications for MANF that will bring in enormous money once you've established Proof of Concept.
wxpete.....The company announced Eltoprozine on January 14. Stock spiked over 33% that day. I think that Gerald may have anticipated a similar move with ESS. - (by the way, I'm not Sol.)
wxpete....."position of strength"...He also said, "We will not consider a reverse split at these levels" (share price at that time was just about where it is today). I wholeheartedly believe that the plan was to reverse split / uplist at $0.18. This would convert warrants that would net the company $5.4M. However, I also think that GC is out of touch when it comes to anticipating moves in the stock price. I think that he assumed that the ESS deal would create a much bigger splash than it did, like the Elto acquisition did in January.
Another concern is the possibility that GC has already surrendered to the fate of a 1:100, and that he clued Napodano in, so as to soften the blow a few months in advance. Ultimitely, if they end up doing a 1:100, I would see that as a serious breech on Gerald's part, considering his previous claims. And I would hope that if that were to happen, that he would not make those types of statements in the future, when so many variables could shake up any original plans.